Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Presence of NDMA impurity detected in product.
| Distributed by / for | Preferred Pharmaceuticals, Inc |
| NDC | 68788-6382-1 |
| Full product label | Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 300 mg, Rx Only, a) 14 count bottles (NDC: 68788-6382-1), b) 30 count bottles (NDC: 68788-6382-3), c) 90 count bottles (NDC: 68788-6382-9), d) 100 count bottles (NDC: 68788-6382-0) |
| Recalling firm | Preferred Pharmaceuticals, Inc |
| Distribution | Distribution to physicians in the following states: AL, AZ, CA, FL, GA, IN, and SC |
| Quantity | 39,172 tablets |
| Recall initiated | 2020-01-07 |
| Report date | 2020-01-29 |
| Recall completed | 2023-12-14 |
| Recall number | D-0797-2020 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Anaheim CA United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗